Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases

Radiation necrosis (RN) is a potential late complication of radiotherapy for intracranial malignancy, which is often associated with significant neurological morbidity. Prolonged treatment with high-dose corticosteroids or surgical resection has been the standard care for RN, but protracted steroid use can lead to significant side effects and surgical resection is not always feasible. The antivascular endothelial growth factor monoclonal antibody bevacizumab induces clinical and radiographic improvements in RN, with overall good tolerance. However, evidence supporting its use for RN in melanoma brain metastases is minimal, likely secondary to concern for intracranial bleeding. Immunotherapy is now one of the most commonly used and effective therapies for metastatic melanoma. A higher risk of RN has been reported with immunotherapy, making alternative treatment for RN in this population a priority, especially as prolonged use of steroids may counteract the treatment efficacy of immunotherapy. We report on seven melanoma patients who developed RN after stereotactic radiosurgery with or without whole-brain radiation therapy who were treated with 2–6 doses of bevacizumab. All patients experienced improvements in symptoms and quality of life, with a concurrent improvement in imaging in six patients. Furthermore, bevacizumab was well tolerated and none of the seven patients experienced intracranial or extracranial bleeding. Our series suggests that in selected melanoma brain metastases patients, bevacizumab may be a safe and effective treatment for RN, especially for those who are undergoing immunotherapy, and should be further evaluated in a prospective setting.

[1]  D. Fried,et al.  The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy , 2017, Anti-cancer drugs.

[2]  H. Tawbi,et al.  Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma , 2017, Journal of Neuro-Oncology.

[3]  D. Schadendorf,et al.  Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  H. Kluger,et al.  Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? , 2016, Journal of neurosurgery.

[5]  G Vogin,et al.  Radionecrosis after stereotactic radiotherapy for brain metastases , 2016, Expert review of neurotherapeutics.

[6]  K. Sugiyama,et al.  A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis† , 2016, Neuro-oncology practice.

[7]  Yoshiya Yamada,et al.  Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases , 2015, Journal of Neuro-Oncology.

[8]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[9]  S. Miyatake,et al.  Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain , 2014, Neurologia medico-chirurgica.

[10]  D. Hallahan,et al.  Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain , 2014, Clinical Cancer Research.

[11]  K. Slavin,et al.  An analysis of radiation necrosis of the central nervous system treated with bevacizumab , 2014, Journal of Neuro-Oncology.

[12]  A. Buzaid,et al.  Low-Dose Bevacizumab Is Effective in Radiation-Induced Necrosis , 2013, Case Reports in Oncology.

[13]  Y. Yamada,et al.  Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. , 2013, Neuro-oncology.

[14]  Nicholas F. Marko,et al.  Cerebral radiation necrosis: A review of the pathobiology, diagnosis and management considerations , 2013, Journal of Clinical Neuroscience.

[15]  Andrea Doria,et al.  The kaleidoscope of glucorticoid effects on immune system. , 2011, Autoimmunity reviews.

[16]  M. Gilbert,et al.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. , 2011, International journal of radiation oncology, biology, physics.

[17]  J. Uhm Bevacizumab Safety in Patients with Central Nervous System Metastases , 2010 .